Profiling of Proteins Regulated by Venlafaxine during Neural Differentiation of Human Cells

Mi Sook Doh1, Dal Mu Ri Han1, Dong Hoon Oh2, Seok Hyeon Kim2, Mi Ran Choi1 3, and Young Gyu Chai1 3

1Department of Molecular and Life Sciences, Hanyang University, Ansan, Republic of Korea
2Department of Neuropsychiatry, College of Medicine and Institute of Mental Health, Hanyang University, Seoul, Republic of Korea

Objectives

Antidepressants are known to positively influence several factors in patients with depressive disorders, resulting in increased neurogenesis and subsequent relief of depressive disorders. To study the effects of venlafaxine during neural differentiation at the cellular level, we looked at its effect on protein expression and regulation mechanisms during neural differentiation.

Methods

After exposing NCCIT cell-derived EBs to venlafaxine during differentiation (1 day and 7 days), changes in protein expression were analyzed by 2-DE and MALDI-TOF MS analysis. Gene levels of proteins regulated by venlafaxine were analyzed by real-time RT-PCR.

Results

Treatment with venlafaxine decreased expression of prolyl 4-hydroxylase (P4HB), ubiquitin-conjugating enzyme E2K (HIP2) and plastin 3 (T-plastin), and up-regulated expression of growth factor beta-3 (TGF-β3), dihydropyrimidinase-like 3 (DPYSL3), and pyruvate kinase (PKM) after differentiation for 1 and 7 days. In cells exposed to venlafaxine, the mRNA expression patterns of HIP2 and PKM, which function as negative and positive regulators of differentiation and neuronal survival, respectively, were consistent with the observed changes in protein expression.

Conclusion

Our findings may contribute to improve understanding of molecular mechanism of venlafaxine.

Key Words
Venlafaxine, Depression, NCCIT cells, Proteomics, HIP2, Pyruvate kinase.

INTRODUCTION

Treatment with antidepressants promotes a rapid increase in levels of monoamines in the synaptic cleft, whereas the clinical effects of antidepressants are observed only after several weeks to months. Previous studies have shown that chronic treatment of antidepressants such as tianeptine and fluoxetine increases expression of brain-derived neurotropic factor (BDNF), mitogen-activated protein kinase, Bcl-xL, and NCAM140, as well as increases cell survival, suggesting that antidepressants affect the cellular and molecular mechanisms in the brain in addition to increasing levels of monoamines.

The mechanisms of antidepressants associated with stress and depression have been persistently studied both in vitro and in vivo. Stress and/or depression suppress neurogenesis in the subgranular zone (SGZ) of the adult hippocampus. It has been reported that depressive disorders induce atrophy and decrease the volume of the hippocampal region of the brain. On the other hand, chronic treatment with antidepressants such as fluoxetine results not only in recovery of stress-induced decreases in neurogenesis, but also improves cell proliferation in the SGZ of the adult hippocampus, suggesting the involvement of complex processes such as neural plasticity.

Several previous studies have utilized proteomic analysis to evaluate the mechanisms of action of antidepressants. Khawaja et al. found that chronic treatment of rats with antidepressants (14 days) including fluoxetine and venlafaxine, induced changes in the expression of proteins in the hippocampus that are involved with cellular proliferation, differentiation, apoptosis, and survival mechanisms. Likewise, Cecconi et al. identified differently expressed proteins in rat...
Protein Profiling in Venlafaxine-Exposed ECCs

cortical neurons after fluoxetine treatment for 3 days, which were associated with neuroprotection, serotonin biosynthesis, and axonal transport. Similarly, treatment of mouse embryonic stem (ES) cell-derived neural cells with toparoxetin for 14 days strongly upregulates the expression of proteins related to the synthesis of neurotransmitters. Together, these results suggest that antidepressants positively influence neurons both before and after ES cell differentiation to relieve depressive disorders through various molecular and cellular mechanisms.

In particular, venlafaxine is one of serotonin-norepinephrine reuptake inhibitors (SNRIs), which increase the levels of both serotonin and norepinephrine in the synaptic cleft by blocking transport of both monoamines. Several studies suggest that venlafaxine is more effective than serotonin selective reuptake inhibitors (SSRIs) such as fluoxetine. However, there is insufficient evidence to indicate a molecular mechanism of antidepressants associated with various network pathways at the transcriptomic and proteomic levels during neural differentiation.

Human embryonic carcinoma (EC) cells are pluripotent stem cells derived from malignant teratocarcinoma and are considered to be in same category as human ESCs. Importantly, EC cells are easier to handle than ES cells with respect to studying the molecular and cellular mechanisms of cell differentiation during embryonic development. In addition, one of human EC cell line, NCCIT cells are known to induce multilineage differentiation upon exposure to retinoic acid (RA) in vitro. Gasimli et al. observed distinct morphological changes, showing branched elongated process of neuronal morphology after 20 days of RA treatment in NCCIT cells. As a result of aggregates, ES cells or EC cells can spontaneously form embryonic bodies (EBs) in vitro. Tonge et al. observed that neural gene expression was increased in RA-treated EBs of human ES cells compared to monolayer of cells.

To study the effects of venlafaxine during neural differentiation at the cellular level, we induced differentiation of NCCIT cells by exposing them to RA in the presence or absence of venlafaxine. We identified proteins that were regulated by venlafaxine during neural differentiation using proteomic analysis and examined the mechanisms by which the identified proteins were regulated during differentiation. The proteins that were identified as being regulated by venlafaxine in this study may contribute to a better understanding of the molecular mechanism by which venlafaxine treatment relieves depressive disorders.

METHODS

NCCIT cell culture and embryonic body formation

The NCCIT cell line (CRL-2073) was obtained from the ATCC (Manassa, VA, USA). Cells were cultured in RPMI-1640 medium (Invitrogen, CA, USA) containing 10% fetal bovine serum (Invitrogen), 100 U/mL penicillin, and 10 µg/mL streptomycin (Invitrogen) at 37°C in a humidified atmosphere with 5% CO₂. To induce the formation of EBs, NCCIT cells were transferred to 90-mm bacterial culture dishes for non-adherent culture condition for 7 days. The culture medium was replaced every 2 days with fresh medium.

Venlafaxine treatment during neural differentiation of EBs

To evaluate the effects of venlafaxine during neural differentiation, EBs derived from NCCIT cells were seeded in 100-mm tissue culture dishes and incubated with differentiation medium containing 10 µM RA in the absence or presence of 10 µM venlafaxine (Wyeth Korea, Seoul, Korea) (Figure 1A). The 10 µM concentration of venlafaxine was decided as was done in previous studies that the concentration did not induce apoptosis. Cultures were fed with fresh differentiation medium every 2 to 3 days up to 7 days.

Immunocytochemistry

EBs derived from NCCIT cells were plated onto cover slips pre-coated with poly-L-lysine (Sigma-Aldrich, MO, USA) in RPMI 1640 medium containing 10% fetal bovine serum and 1% penicillin/streptomycin. After differentiation (1 day or 7 days), the cells were fixed with 4% paraformaldehyde and permeabilized with 100% ice-cold methanol, then washed with PBS containing 0.04% sodium azide and incubated in PBS containing 0.04% sodium azide and incubated in PBS containing 5% horse serum (Sigma-Aldrich) for 1 h. The cells were incubated with primary antibodies against beta-tubulin III (Tu-20, 1:200) (Millipore, MA, USA), glial fibrillary acidic protein (GFAP, 1:300) (Dakocytomation, Glostrup, Denmark), O4 (1:200) (Chemicon, CA, USA), and Nestin (1:250) (Chemicon) for 1 h at room temperature. The cells were then washed with PBS and incubated with fluorescein-labeled anti-rabbit IgG (H+L) (Jackson ImmunoResearch, PA, USA) and fluorescein-labeled anti-mouse IgG (H+L) (Jackson ImmunoResearch). The stained cells were visualized with a mounting solution containing 4′-6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, Burlingame, CA, USA) and observed using an ECLIPSE 80i fluorescence microscope (Nikon, Tokyo, Japan).

Two-dimensional gel electrophoresis

For 2D gel electrophoresis, immobilized pH gradient (IPG) dry strips were equilibrated for 12-16 h with reswelling solution containing 7 M urea, 2% 3-[(3-cholamidopropyl) dimethyammonio]-1-propanesulfonate (CHAPS), 1% dithiothreitol (DTT), and 1% pharmalyte. Next, 200 µg of the samples
were loaded onto the strip; protein concentrations were determined by Bradford assay (Sigma-Aldrich). Isoelectric focusing (IEF) was carried out at 20°C using a Multiphore II system (Amersham Biosciences, NJ, USA) and EPS 3500 XL power supply (Amersham Biosciences) according to the manufacturer’s instructions. Prior to the second dimension, the focused IPG strips were reduced (1% DTT) and alkalized (2.5% iodoacetamide) in equilibration buffer (50 mM Tris-Cl, pH 6.8 containing 6 M urea, 2% SDS and 30% glycerol). SDS-PAGE was then performed with a Hoefer DALT 2D system (Amersham Biosciences) at 20°C. Two-dimensional gel electrophoresis (2-DE) gels were stained with Coomassie Brilliant Blue dye. Analysis of imaged spots was performed using PDQuest software (version 7.0, BioRad). To determine the relative levels of protein in each individual spot, the spot volume of each protein was compared to that of a normalized protein volume.

**In-gel digestion**

Differentially expressed protein spots were enzymatically digested in gel using modified porcine trypsin (Promega, WI, USA) as previously described. Briefly, SDS and salts were removed by washing gel pieces with 50% acetonitrile followed by drying to remove the solvent. The washed gels were then rehydrated with trypsin (8–10 ng/μL) and incubated for 8–10 h at 37°C. The proteolytic reaction was terminated by the addition of 20 µL of 0.1% trifluoroacetic acid. Tryptic peptides were recovered by extraction in 50% aqueous acetonitrile, and aqueous phase extractions of replicate gel pieces were combined. An aliquot of the solution was mixed with an equal volume of saturated solution of α-cyano-4-hydroxycinnamic acid in 50% aqueous acetonitrile, and 1 µL of the mixture was spotted on the target plate.

**MALDI-TOF MS analysis and database search**

Peptide analysis was performed using an Ultraflex MALDI-TOF MS (Bruker Daltonics, Bremen, Germany). Briefly, peptides were evaporated with an N₂ laser at 337 nm using a delayed extraction approach and accelerated with a 20 kV injection pulse for TOF analysis. Each spectrum was the cu-
Protein Profiling in Venlafaxine-Exposed ECCs

Cumulative average of 300 laser pulses. Proteins were identified by peptide mass fingerprinting using the ProFound search program developed by Rockefeller University (http://prowl.rockefeller.edu/prowl-cgi/profound.exe). Spectra were calibrated using trypsin autodigestion ion peak signals (m/z 842.510 and 2211.1046) as internal standards.

Pathway network analysis

Integrated pathway enrichment analysis was performed using knowledge-based canonical pathways and the endogenous metabolic pathways of MetaCore pathway analysis software (GeneGo Inc, MI, USA). Briefly, differentially expressed proteins were mapped to biological networks using a manually curated proprietary database (GeneGo) and MetaCore pathway analysis software; gene symbols of differentially expressed proteins were uploaded into the GeneGo database. For enrichment analysis, the gene IDs of the uploaded files were matched with the gene IDs of functional ontologies in MetaCore, which included canonical pathway maps (GeneGo maps), GeneGo cellular processes, Gene Ontology (GO) cellular process, and disease categories. The canonical pathway maps comprised a set of approximately 500 signaling and metabolic maps covering human biology. For network analysis, we utilized the analyze networks, transcription regulation, and direct interactions algorithms. The analyze networks algorithm, a variant of the shortest paths algorithm, uses relative enrichment and relative saturation to generate sub-networks that are prioritized by the number of associated canonical pathways.

Real-time RT-PCR of genes regulated during neural differentiation of EBs exposed to venlafaxine

Total RNA from cells differentiated in the absence or presence of 10 µM venlafaxine for 1 or 7 days was extracted using TRIzol® Reagent (Invitrogen) according to the manufacturer’s instructions. Extracted total RNA was reverse transcribed into cDNA using PrimeScript™ Reverse Transcriptase (Taka ra, Shiga, Japan). Real-time PCR was performed using the 7500 real-time PCR system (Applied Biosystems, CA, USA) with 2X SYBR Green PCR Master Mix (Takara) as previously described. reactionmixtures contained 2X SYBR Green PCR Master Mix, 8 pmol each of forward and reverse primer, and 0.5 µL cDNA. During each cycle, the accumulation of PCR products was detected by measuring the increase in fluorescence of a double stranded DNA-binding SYBR Green reporter dye. β-actin was used as an internal control. The sequences of primers are listed in Table 1.

Statistical analysis

All of the data are expressed as the mean±standard error of the mean (SEM) and were analyzed using OriginPro 8 (Origin-Lab Corporation, MA, USA). Statistical analyses were performed using SPSS 17.0 (SPSS Inc., IL, USA). p-values<0.05 were considered significant.

RESULTS

Differentiation potential of EBs after exposure to venlafaxine

To identify the effects of venlafaxine on differentiation of EBs derived from NCCIT cells, we induced differentiation of EBs in the presence or absence of venlafaxine for 1 or 7 days and measured differentiation potential by immunocytochemistry. In EBs derived from NCCIT cells, all of the tested markers related to central nervous system development were expressed after 1 day of differentiation (Figure 1B). The levels of expression of GFAP and Nestin, which are astrocyte and neuronal stem cell markers, respectively, were decreased for 7 days in both venlafaxine-treated and control cells. On the other hand, the signal intensity of the neuron marker TU-20 in venlafaxine-treated cells was not significantly different compared with control cells. As 7 day-differentiation of EBs derived from NCCIT cells into neurons were at an early stage, the signal intensity of the neuron marker was weak in both venlafaxine-treated and control cells. Thus, at the early stage of neuronal differentiation evaluated in our study, it was difficult to detect the effect of venlafaxine on early stage neuronal differentiation by immunocytochemistry.

Regulation of proteins by venlafaxine during neural differentiation of NCCIT cells

To analyze the proteins regulated by venlafaxine during

| Amplicon | Forward (5’-3’) | Reverse (5’-3’) |
|----------|----------------|----------------|
| HIP2     | GTTCCGTCACAGGGGCTATT | AATACCGGTGGGAGGTCATT |
| P4HB     | TGACACCTCACCCCTACACA | ACTCCGACACCGGAGCAAG |
| T-plastin| TGCCATCCACAGGATTTCCA | TCACAAATGATACGTCCTG |
| PKM      | ATGTCGAAGCCCATAGTGAA | TGCCGTTGCAATGACCAAC |
| DPYSL3   | AAAACCCAGTGGAGAAAATG | TGACCTTGTGACGGAGAGG |
| TGF-β3   | GGAAAAACCCGAGTGGGAATAC | GCGGAAAACCTTGGAGGTAAT |
neural differentiation of NCCIT cells, we performed a 2DE assay after exposing EBs to 10 μM venlafaxine for 1 or 7 days. Of the spots obtained from the 2DE gel, those that were differentially regulated by venlafaxine were analyzed by MALDI-TOF MS. Among the proteins that were up-regulated in cells treated with venlafaxine after differentiation for 1 day, we identified ruvB-like 2 (RUVBL2), elongation factor Tu (TUFM), heat shock protein 90-beta (HSP90AB1), pyruvate kinase (PKM), transforming growth factor beta-3 (TGF-β3), and alpha enolase (ENO1) (Table 2). Likewise, expression of PKM, dihydropyrimidinase-like 3 (DPYSL3), DNA replication licensing factor (MCM7), epidermal growth factor receptor (EGFR), and ENO1 were up-regulated by venlafaxine after differentiation for 7 days (Table 3). TUFM, PKM, TGF-β3, ENO1, DPYSL3, MCM7, and EGFR are associated with cellular growth, differentiation, and proliferation, and thus we considered the possibility that venlafaxine may positively influence neural differentiation. Conversely, ubiquitin-conjugating enzyme E2 K isoform 1 (HIP-2), lamin A/C, eukaryotic translation initiation factor 4H (EIF4H), ribosomal protein, large, P0 (RPLP0), and tubulin beta (TUBB) protein were down-regulated by venlafaxine after differentiation for 1 day (Table 2), while BP-like protein 2 (TM2D3), plastin3 (T-Plastin), and protein disulfide-isomerase precursor (P4HB) proteins described in bold letter are validated using real-time RT PCR. ND: not detected.

Table 2. The summarized list of up- or down-regulated proteins in the differentiated cells in the presence of venlafaxine for 1 day as compared to the control

| Protein                                      | Spot intensity | Ratio  | Estimated Z | Accession number |
|----------------------------------------------|----------------|--------|-------------|------------------|
| RuB-like 2                                  | ND             | 659.58 | 2.39        | gi|5730023          |
| Annexin A2                                  | ND             | 651.88 | 1.45        | gi|16306978         |
| Thioredoxin-like 1 variant                  | ND             | 401.26 | 1.66        | gi|62088106         |
| Septin-2                                    | ND             | 387.23 | 1.58        | gi|4758158          |
| Esterase D/formylglutathione hydrolase       | ND             | 339.35 | 2.33        | gi|55957281         |
| Elongation factor Tu                        | ND             | 211.20 | 2.23        | gi|704416           |
| PHIP protein                                | ND             | 50.47  | 1.78        | gi|116284001        |
| UPF0556 protein C19orf10 precursor          | 9.42           | 251.14 | 2.07        | gi|33554555         |
| 3-hydroxyacyl-CoA dehydrogenase type-2 isoform 2 | 38.52          | 203.18 | 2.17        | gi|83715985         |
| Rab GDP dissociation inhibitor alpha         | 137.58         | 648.06 | 1.93        | gi|4503971          |
| SP3 protein                                 | 283.67         | 1275.97| 0.69        | gi|34783623         |
| Cell growth regulator with RING finger domain protein 1 | 33.11       | 138.36 | 1.48        | gi|158259979        |
| Alpha enolase                               | 232.08         | 669.70 | 2.35        | gi|2661039          |
| Tumor rejection antigen (gp96) 1 variant    | 109.81         | 316.80 | 1.58        | gi|62088648         |
| Heterogeneous nuclear ribonucleoproteins C1/C2 variant | 624.11       | 1683.85| 2.26        | gi|189065461        |
| Ankyrin repeat domain-containing protein 46 | 163.48        | 405.16 | 2.18        | gi|38257146         |
| Pyridoxal phosphate phosphatase             | 228.21         | 564.02 | 2.15        | gi|10092677         |
| Heterogeneous nuclear ribonucleoprotein H3 isoform a | 105.81       | 258.22 | 2.28        | gi|14141157         |
| Heat shock protein 90-beta                  | 430.51         | 1046.08| 1.88        | gi|20149594         |
| Pyruvate kinase (PKM)*                      | 717.22         | 1716.93| 2.38        | gi|35505            |
| Ribosomal protein, large, P0, isoform CRA_a  | 715.40         | 1686.07| 2.43        | gi|119618576        |
| Transforming growth factor beta-3 (TGF-β3)* | 548.77         | 1272.86| 0.95        | gi|4507465          |
| MHC class I antigen                         | 62.94          | 31.23  | 1.37        | gi|360580953        |
| Plastin-3 isoform 1 (T-plastin)*            | 906.38         | 425.39 | 0.47        | gi|7549809          |
| Ubiquitin-conjugating enzyme E2 K isoform 1 (HIP-2)* | 383.04       | 150.54 | 0.62        | gi|4885417          |
| Lamin A/C, isoform CRA_d                    | 388.70         | 135.99 | 0.35        | gi|119573385        |
| Eukaryotic translation initiation factor 4H isoform 2 | 315.86       | 91.09  | 1.27        | gi|14702180         |
| Ribosomal protein, large, P0                | 369.50         | 88.68  | 1.76        | gi|12654583         |
| Tubulin, beta                               | 413.05         | 76.15  | 2.22        | gi|12804891         |

*proteins described in bold letter are validated using real-time RT PCR. ND: not detected
were down-regulated by venlafaxine after differentiation for 7 days (Table 3).

**Identification of potential networks of proteins regulated by venlafaxine**

To explore the GeneGo Process Networks for proteins regulated by venlafaxine during neural differentiation, we used MetaCore database and MetaCore pathway analysis software (GeneGo Inc.). The MetaCore database is well suited for analyzing manually curated interactions and contains >90% of human proteins with known functions. We identified top scoring networks that were common to both venlafaxine-treated and control cells during neural differentiation (Figure 2). The highest scoring networks that were regulated by venlafaxine on differentiation for 1 day included TGF-β3, PKM, and HIP-2, which are involved in negative regulation of biological process (63.3%) and regulation of apoptosis (44.7%) (Figure 2A). Likewise, the highest scoring networks that were regulated by venlafaxine on differentiation for 7 days included damage-specific DNA binding protein 1 (DDB1), PKM, and P4HB, which are involved in response to chemical stimulus (76.0%) and regulation of biological quality (60.0%) (Figure 2B).

**Validation of mRNA levels of protein regulated by venlafaxine**

Although post-translational modification and protein turn-

### Table 3. The summarized list of up- or down-regulated proteins in the differentiated cells in the presence of venlafaxine for 7 days as compared to the control

| Protein                                      | Spot intensity | Control | Venlafaxine | Ratio  | Estimated Z | Accession number |
|----------------------------------------------|----------------|---------|-------------|--------|-------------|-----------------|
| Alpha enolase                                | ND             | 1266.99 | 1266.99     | 2.34   |             | gi|2661039         |
| Malectin precursor                           | ND             | 532.78  | 532.78      | 2.10   |             | gi|7661948         |
| Dihydropyrimidinase-like 3 (DPYL3)*          | ND             | 303.15  | 303.15      | 2.38   |             | gi|24659471        |
| Seryl-tRNA synthetase                        | ND             | 252.53  | 252.53      | 2.34   |             | gi|1050527         |
| Matrin-3 isoform a                           | ND             | 131.16  | 131.16      | 0.79   |             | gi|21626466        |
| Thioredoxin isoform 1                        | 13.17          | 297.60  | 22.60       | 0.81   |             | gi|50592994        |
| Proteasome subunit HsN3                      | 11.07          | 141.89  | 12.82       | 1.76   |             | gi|565651          |
| Proteasome subunit alpha type-1 isoform 2    | 55.70          | 307.59  | 5.52        | 2.43   |             | gi|4506179         |
| Epidermal growth factor receptor             | 116.10         | 593.45  | 5.11        | 1.87   |             | gi|41327732        |
| DNA replication licensing factor MCM7 isoform 1| 110.34         | 414.59  | 3.76        | 2.35   |             | gi|33469968        |
| Ubiquitin-conjugating enzyme E2 N            | 123.95         | 439.28  | 3.54        | 2.40   |             | gi|4507793         |
| Fibroblast growth factor receptor            | 104.27         | 317.00  | 3.04        | 1.57   |             | gi|31372           |
| ZNF451 protein                               | 139.02         | 412.27  | 2.98        | 2.04   |             | gi|27769235        |
| Interleukin 10 receptor, beta, isoform CRA_a  | 171.08         | 499.41  | 2.92        | 0.74   |             | gi|119630245       |
| RNA polymerase III subunit                   | 245.46         | 712.19  | 2.90        | 1.34   |             | gi|2228752         |
| Chain B, Crystal Structure Of The Brct Domains of Human 53bp1 Bound To The P53 Tumor Suppressor | 145.09         | 414.75  | 2.86        | 2.43   |             | gi|21730309        |
| ALG-2 interacting protein 1                  | 113.41         | 287.89  | 2.54        | 2.29   |             | gi|6424942         |
| Pyruvate kinase (PKM)*                       | 330.49         | 729.37  | 2.21        | 1.57   |             | gi|35505           |
| Epidermal growth factor receptor kinase substrate 8-like protein 3 isoform c | 1295.85        | 629.01  | 2.13        | 0.79   |             | gi|21071014        |
| T-complex protein 1 subunit epsilon           | 278.66         | 591.79  | 2.12        | 2.21   |             | gi|24307939        |
| Glyoxalase I                                 | 197.20         | 413.63  | 2.11        | 1.37   |             | gi|15030212        |
| Protein inhibitor of activated STAT, 2, isoform CRA_b | 110.42         | 228.83  | 2.07        | 0.70   |             | gi|119621890       |
| Radixin                                      | 286.88         | 591.50  | 2.06        | 2.39   |             | gi|4506467         |
| T-plastin polypeptide*                       | 198.17         | 128.00  | 0.65        | 2.07   |             | gi|4507651         |
| BBP-like protein 2                           | 589.97         | 167.63  | 0.28        | 0.69   |             | gi|4503971         |
| Targeting protein for Xklp2                  | 224.35         | 53.08   | 0.24        | 1.39   |             | gi|67464627        |
| Protein disulfide-isomerase precursor (P4HB)* | 3705.79        | 598.42  | 0.16        | 2.41   |             | gi|57209813        |

*proteins described in bold letter are validated using real-time RT PCR. ND: not detected
over can affect the levels of protein expression, determining that an identified protein target is regulated at the mRNA level provides corresponding evidence of the reliability of the relative quantitative protein expression results. Thus, we measured transcript levels of selected proteins using real-time RT-PCR. Similar to the proteomic expression pattern, the expression levels of HIP2 and T-plastin mRNA were decreased while levels of PKM and TGF-β3 mRNA were increased in venlafaxine-treated cells compared to control cells after differentiation for 1 day (Figure 3A and B). After differentiation for 7 days, the levels of expression of P4HB and T-plastin mRNA were significantly decreased, while the expression of PKM and DPYSL3 mRNAs were increased in venlafaxine-treated cells compared to control cells. Together, these results corresponded with the observed patterns of protein expression (Figure 3C and D). On the other hand, although expression of DPYSL3 and HIP2 proteins could not be detected after 1 and 7 days of differentiation, respectively, changes in their expression at the mRNA level were confirmed. Based on these results, it appeared that, beginning almost immediately after initiation of differentiation and up to 7 days later, treatment with venlafaxine increased consistently levels of DPYSL3 and levels of HIP2 gradually decreased. Together, these data served to validate several proteins obtained from proteomic profiling, as well as provided information regarding estimated expression levels of proteins that were identified at only a single time point by proteomic analysis.

DISCUSSION

Neurogenesis progresses through the interactions of various factors associated with survival, differentiation, metabolism, and proliferation. Antidepressants are known to positively affect these factors in patients with depressive disorders, resulting in increased neurogenesis and subsequent relief of depressive disorders. Therefore, it is meaningful to identify proteins regulated by antidepressants under in vitro conditions, as this information can provide clues about the complex network of interactions that take place between antidepressants and cells in the brain. In the present study, we used proteomic analysis to identify proteins that were differentially regulated by venlafaxine during neural differentiation of NCCIT cells.

The results of our study showed that after 1 and 7 days of neural differentiation of EBs, venlafaxine did not significantly alter expression of the neuronal marker TU-20 at the cellular level. These results were consistent with previous studies showing that NCCIT cells differentiate into neurons after 3–4 weeks of continuous exposure to RA in vitro and administration of rolipram, an antidepressant, to mice for 14 days.
promotes maturation of new neurons, because the maximum treatment with venlafaxine in our study was 7 days.

In the present study, TGF-β3 and DPYSL3 were up-regulated after 1 and 7 days of differentiation and treatment with venlafaxine. The TGF-β subfamily comprises TGF-β1, 2, and 3, all of which are highly expressed during development of the nervous system and are responsible for differentiation and survival of neurons. It has already been reported that chronic treatment of venlafaxine in patients with major depressive disorder increases expression of TGF-β1. However, unlike TGF-β1, the effect of antidepressants on the expression of TGF-β3 has hardly been studied. Recently, Wu et al. demonstrated that transient transduction of TGF-β3 by intra-amniotic gene transfer prevents cleft palate in Tgfβ3−/− mouse embryos. This finding suggests that TGF-β3 may be involved in embryonic development as well as development of the nervous system. Together with our observation that TGF-β3 was up-regulated by venlafaxine treatment during neural differentiation, the involvement of TGF-β3 in inhibiting cleft palate suggests that venlafaxine positively engages developmental processes via control of TGF-β3.

DPYSL3, also known as collapsing response mediator protein 4 (CRMP4), is involved in neuronal differentiation, neuronal regeneration, and outgrowth of neurites and axons. DPYSL3 is highly expressed in the adult brain, and its expression can be observed in new neurons during adult rat neurogenesis. In addition, CRMP2, one of CRMP family members, plays a pivotal role in outgrowth of axons and dendrites. In a study of Yoshimura et al., the knockdown of CRMP2, a member of CRMP family, inhibited BDNF-induced axon elongation and branching, indicating that CRMP2 is associated with BDNF-induced axon outgrowth. As a result, CRMP family including CRMP2 and CRMP4 plays a pivotal role in growing axon of neurons. It was previously reported that the mRNA expression levels of TOAD-64, a member of the DPYSL3 family, are increased in the EC cell line P19 following exposure to RA during early neuronal differentiation. These findings suggest that the DPYSL3 family, including...
TOAD-64, may play an important role in neuronal differentiation and acquisition of a neuronal phenotype. In our study, the expression of DPYSL3 mRNA in cells undergoing differentiation and treated with venlafaxine for 1 day was significantly increased. The expression of DPYSL3 mRNA and protein after treatment with venlafaxine for 7 days was also increased compared with control cells; however, there was a noticeable difference between mRNA and protein expression compared with control cells. Together with previous studies, our data suggest that venlafaxine may affect neuronal differentiation by facilitating up-regulation of DPYSL3.

The expression levels of PKM mRNA and protein were up-regulated by treatment with venlafaxine after differentiation for 1 and 7 days. In glycolysis, PKM functions to generate pyruvate and glycolytic ATP to provide energy for living cells. Glucose metabolism in the brain not only is essential for normal function but also plays an important role in synaptic transmission. Ishida et al. have shown that PKM is responsible for transporting neurotransmitters such as GABA, dopamine, and serotonin into synaptic vesicles. In addition, they identified that PKM regulates the transfer of glutamate into synaptic vesicles through ATP consumption. Also, Glutamate and serotonin signaling are associated with synaptic plasticity, BDNF transcript and other neurotrophic factors. Bani-Yaghoub et al. showed that PKM is up-regulated during differentiation of the human teratocarcinoma line NT2/D1 into neurons, indicating that differentiation itself encourages the expression of proteins associated with metabolic mechanisms. In addition, Ryou et al. suggested that pyruvate has protective effects against ischemia-reperfusion brain injury. Consistent with these findings, we identified up-regulation of PKM by venlafaxine during neural differentiation. These results suggest that PKM is involved in pyruvate metabolism pathway, thus it may affect cellular differentiation and survival as well as events involved in neurotransmission.

The expression levels of P4HB mRNA and protein were significantly decreased after differentiation for 7 days and simultaneous treatment with venlafaxine. On the contrary, there was no difference between venlafaxine-treated cells and control cells after differentiation for 1 day. P4HB, known as protein disulfide isomerase (PDI), catalyzes the formation, isomerization, and breakage of disulfide linkages. P4HB has been reported to have opposing functions inside cells based on its concentration. Specifically, at high concentrations, P4HB suppresses aggregation of misfolded proteins, while at low concentrations, it promotes aggregation. On the other hand, a previous study showed that the toxicity of mutant huntingtin exon1 and Aβ peptides derived from amyloid precursor proteins could be inhibited by suppressing P4HB in rat brain cells. As suggested by others, this observation suggests the possibility that P4HB is a novel target for developing therapies for neurodegenerative disorders such as Huntington’s disease and Alzheimer’s disease. Based on previous reports and our own observation that chronic treatment of venlafaxine in vitro decreases expression of P4HB, additional studies associated with the cellular effects of antidepressants on the function of P4HB are warranted.

We found that treatment with venlafaxine resulted in decreased expression of not only HIP2 mRNA and protein after differentiation for 1 day, but also HIP2 mRNA after differentiation for 7 days. HIP2 is well known to interact with huntingtin, and affects the pathogenesis of both Huntington’s and Alzheimer’s disease. In addition, HIP2 promotes aggregate formation and cell death in polyglutamine-induced neurodegeneration. Likewise, Song et al. recently showed that knockdown of HIP2 in cortical neurons inhibits neuron death by endoplasmic reticulum stress. Taken together, the observed decrease in HIP2 expression by venlafaxine during neural differentiation suggests the possibility of venlafaxine as a drug candidate for treating neurodegenerative diseases in addition to depressive disorders.

Finally, we used MetaCore pathway analysis software (GeneGo Inc.) to identify top scoring networks that appeared to be involved in the effects of venlafaxine by analyzing differentially expressed proteins after neural differentiation for 1 and 7 days. The observed networks may offer useful information concerning physical connectivity and functional relationships among proteins that were differentially regulated by venlafaxine. Recently, rapid antidepressant action of ketamine has been focused on the mechanisms of novel treatment in depression. Mammalian target of rapamycin (mTOR) signaling pathway underlie rapid antidepressant effects. Yu et al. observed that venlafaxine prevented the effect of calcineurin inhibitor, which increased depressive-like behavior and reduced mTOR activity. In this study, we found that PKM and TGF-β regulated by venlafaxine were involved in activation of mTOR signaling pathway.

In conclusion, we identified proteins that were differentially regulated by venlafaxine during neural differentiation of EBs derived from NCCIT cells. In particular, PKM was significantly up-regulated by venlafaxine during early RA induced-differentiation of EBs, while HIP2 was significantly down-regulated. Our findings suggest several proteins regulated by venlafaxine that are associated with cellular differentiation, survival of cells, cytoskeleton remodeling and metabolism of cell growth and proliferation. Also, these proteins are related with cytoskeleton remodeling pathway of neurofilament, pyruvate metabolism pathway and apoptosis and survival pathway. Based on our findings, treatment with venlafaxine may af-
fect neural differentiation in human embryonic carcinoma cells. Furthermore, these results will improve our understanding of the molecular mechanisms of venlafaxine.

Acknowledgments

This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Korean Government (MSIP) (No. 2012-0009212; No. 2011-0030049).

REFERENCES

1. Duman RS, Heninger GR, Nestler EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry 1997;54:597-606.
2. Wong ML, Licinio J. Research and treatment approaches to depression. Nat Rev Neurosci 2001;2:343-351.
3. Chiou SH, Chen SJ, Peng CH, Chang YL, Ku HH, Hsu WM, et al. Fluoxetine up-regulates expression of cellular FLICE-inhibitory protein and inhibits LPS-induced apoptosis in hippocampus-derived neural stem cell. Biochem Biophys Res Commun 2006;343:391-400.
4. Reagan JP, Hendry RM, Remizikov LR, Piroli GG, Wood GE, McEwen BS, et al. Tiametine increases brain-derived neurotrophic factor expression in the rat amygdala. Eur J Pharmacol 2007;565:68-75.
5. Reiterson GW, Mastronardi CA, Licinio J, Wong ML. Repeated antidepressant treatment increases cyclic GMP signaling in rat hippocampus. Neurosci Lett 2009;466:49-53.
6. Choi MR, Oh DH, Kim SH, Yang BH, Lee JS, Choi J, et al. Fluoxetine Up-Regulates Bcl-xL Expression in Rat C6 Gliona Cells. Psychiatry Investig 2011;8:161-168.
7. Choi MR, Oh DH, Kim SH, Jung KH, Das ND, Chai YG. Fluoxetine increases the expression of NCAM140 and pCREB in rat C6 glioma cells. Psychiatry Investig 2011:99-104.
8. Warner-Schmidt JL, Duman RS. Hippocampal neurogenesis opposing effects of stress and antidepressant treatment. Hippocampus 2006;16:239-249.
9. Zhao C, Deng W, Gage FH. Mechanisms and functional implications of adult neurogenesis. Cell 2008;132:645-660.
10. Sheline YI, Wang PW, Gado MH, Cermansky JG, Vannier MW. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci U S A 1996;93:3908-3913.
11. Brenner JD, Narayan M, Anderson ER, Staib LH, Miller HL, Charnay DS. Hippocampal volume reduction in major depression. Am J Psychiatry 2001;157:115-118.
12. Malberg JE, Eisch AJ, Nestler EJ, Duman RS. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci 2000;20:9104-9110.
13. Duman RS, Nakagawa S, Malberg J. Regulation of adult neurogenesis by antidepressant treatment. Neuropsychopharmacology 2001;25:836-844.
14. Khawaja X, Xu J, Liang JJ, Barrett JE. Proteomic analysis of protein changes developing in rat hippocampus after chronic antidepressant treatment: Implications for depressive disorders and future therapies. J Neurosci 2004;24:885-91.
15. Cecconi D, Mion S, Astner H, Domenici E, Righetti PG, Carboni L. Proteomic analysis of rat cortical neurons after fluoxetine treatment. Brain Res 2007;1135:41-51.
16. McHugh PC, Rogers GR, Loudon B, Glubb DM, Joyce PR, Kennedy MA. Proteomic analysis of embryonic stem cell-derived neural cells exposed to the antidepressant paroxetine. J Neurosci Res 2008;86:306-316.
17. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001;178:234-241.
18. Smith D, Dempster C, Glanville J, Freemantle N, Anderson I. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychia-try 2002;180:396-404.
19. Spitzer JM, Chen X, Draper JS, Antosiewicz JE, Chen CH, Jones SB, et al. Gene expression patterns in human embryonic stem cells and human pluripotent germ cell tumors. Proc Natl Acad Sci U S A 2003;100:13350-13355.
20. Boyer LA, Lee TL, Cole MF, Johnstone SE, Levine SS, Zucker JP, et al. Core transcriptional regulatory circuitry in human embryonic stem cells. Cell 2005;122:947-956.
21. Han DM, Choi MR, Jung KH, Lee HT, Park JH, Ohn T, et al. Proteomic analysis of the copper ion-induced stress response in a human embryonic carcinoma cell line. Int J Toxicol 2012;31:397-406.
22. Gasimli L, Stansfeld HE, Nairn AV, Liu H, Palah J, Yang B, et al. Structural remodeling of proteoglycans upon retinoic acid-induced differentiation of NCCIT cells. Glycoconj J 2013;30:497-510.
23. Damjanov I, Horvat B, Gibas Z. Retinoic acid-induced differentiation of the developmentally pluripotent human germ cell tumor-derived cell line, NCCIT. Lab Invest 1993;68:220-232.
24. Jung KH, Das ND, Park JH, Lee HT, Choi MR, Chung MK, et al. Effects of acute ethanol treatment on NCCIT cells and NCCIT cell-derived embryoid bodies (EBs). Toxicol in Vitro 2010;24:1696-1704.
25. Tonge PD, Andrews PW. Retinoic acid directs neuronal differentiation of human pluripotent stem cell lines in a non-cell-autonomous manner. Differentiation 2010;80:20-30.
26. Taranger CK, Noer A, Sorensen AL, Hakelem AN, Boquest AC, Collas P. Induction of dedifferentiation, genomewide transcriptional programming, and epigenetic reprogramming by extracts of carcinoma and embryonic stem cells. Mol Biol Cell 2005;16:5719-5735.
27. Yu J, Roh S, Lee JS, Yang BH, Choi MR, Chai YG, et al. The Effects of Venlafaxine and Dexamethasone on the Expression of HSP70 in Rat C6 Glioma Cells. Psychiatry Investig 2010;7:43-48.
28. Chiche F, Le Guillou M, Chertiti G, Lasnier F, Dugail I, Carpenne C, et al. Antidepressant phenelzine alters differentiation of cultured human and mouse preadipocytes. Mol Pharmacol 2009;75:1052-1061.
29. Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 1996;68:850-858.
30. Baik SY, Jung KH, Choi MR, Yang BH, Kim SH, Lee JS, et al. Fluoxetine-induced up-regulation of 14-3-3eta and tryptophan hydroxylase levels in RBL-2H3 cells. Neurosci Lett 2005;374:53-57.
31. Das ND, Jung KH, Chai YG. The role of NF-kappaB and H3K27me3 demethylase, Jmjd3, on the anthrax lethal toxin tolerance of RAW 264.7 cells. PLoS One 2010;5:e9913.
32. Becker S, Wojtowicz JM. A model of hippocampal neurogenesis in memory and mood disorders. Trends Cogn Sci 2007;11:70-76.
33. Castren E, Hen R. Neuronal plasticity and antidepressant actions. Trends Neurosci 2013;36:259-267.
34. Fujioka T, Fujisaka A, Duman RS. Activation of cAMP signaling facilitates the morphological maturation of newborn neurons in adult hippocampus. J Neurosci 2004;24:319-328.
35. Kriegstein K, Strelau J, Schobel A, Sullivan A, Unsicker K. TGF-beta and the regulation of neuron survival and death. J Physiol Paris 2002;96:25-30.
36. Unsicker K, Strelau J. Functions of transforming growth factor-beta isoforms in the nervous system. Cues based on localization and experimental in vitro and in vivo evidence. Eur J Biochem 2000;267:6972-6975.
37. Wu C, Endo M, Yang BH, Radecki MA, Davis PF, Zoltick PW, et al. Intramammalian transient transduction of the peridium with a viral vector encoding TGFβ3 prevents cleft palate in Tgf β3 (-/-) mouse embryos. Mol Ther 2013;21:38-47.
38. Quinn CC, Gray GE, Hockfield S. A family of proteins implicated in axon guidance and outgrowth. J Neurobiol 1999;41:158-164.
39. Quinn CC, Chen E, Kinjo TG, Kelly G, Bell AW, Elliott RC, et al. TUC-4b, a novel TUC family variant, regulates neurite outgrowth and associ-
ates with vesicles in the growth cone. J Neurosci 2003;23:2815-2823.

40. Nacher J, Rosell DR, McEwen BS. Widespread expression of rat collapsin response-mediated protein 4 in the telencephalon and other areas of the adult rat central nervous system. J Comp Neurol 2000;424:628-639.

41. Inagaki N, Chihara K, Arimura N, Menager C, Kawano Y, Matsuo N, et al. CRMP-2 induces axons in cultured hippocampal neurons. Nat Neurosci 2001;4:781-782.

42. Yoshimura T, Kawano Y, Arimura N, Kawabata S, Kikuchi A, Kaibuchi K. GSK-3beta regulates phosphorylation of CRMP-2 and neuronal polarity. Cell 2005;120:137-149.

43. Minturn JI, Fryer HJ, Geschwind DH, Hockfield S. TOAD-64, a gene expressed early in neuronal differentiation in the rat, is related to unc-33, a C. elegans gene involved in axon outgrowth. J Neurosci 1995;15:6757-6766.

44. Sokoloff L. Relation between physiological function and energy metabolism in the central nervous system. J Neurochem 1977;29:13-26.

45. Ishida A, Noda Y, Ueda T. Synaptic vesicle-bound pyruvate kinase can support vesicular glutamate uptake. Neurochem Res 2009;34:807-818.

46. Duman RS, Voleti B. Signaling pathways underlying the pathophysiology and treatment of depression: novel mechanisms for rapid-acting agents. Trends Neurosci 2012;35:47-56.

47. Bani-Yaghoub M, Felker JM, Oozog MA, Bechberger JE, Naus CC. Array analysis of the genes regulated during neuronal differentiation of human embryonic cells. Biochem Cell Biol 2001;79:387-398.

48. Ryoo MG, Liu R, Ren M, Sun J, Mallet RJ, Yang SH. Pyruvate protects the brain against ischemia-reperfusion injury by activating the erythropoietin signaling pathway. Stroke 2012;43:1101-1107.

49. Wilkinson B, Gilbert HF. Protein disulfide isomerase. Biochim Biophys Acta 2004;1699:35-44.

50. Kosuri P, Alegre-Cebollada J, Feng J, Kaplan A, Ingles-Prieto A, Badilla CL, et al. Protein folding drives disulfide formation. Cell 2012;151:794-806.

51. Niatsetskaya Z, Basso M, Speer RE, McConoughy SJ, Coppola G, Ma TC, et al. HIF prolyl hydroxylase inhibitors prevent neuronal death induced by mitochondrial toxins: therapeutic implications for Huntington's disease and Alzheimer's disease. Antioxid Redox Signal 2010;12:435-443.

52. Kwok CT, Morris AG, Frampton J, Smith B, Shaw CE, de Belleruche J. Association studies indicate that protein disulfide isomerase is a risk factor in amyotrophic lateral sclerosis. Free Radic Biol Med 2013;58:81-86.

53. Hoffstrom BG, Kaplan A, Letso R, Schmid RS, Turmel GJ, Lo DC, et al. Inhibitors of protein disulfide isomerase suppress apoptosis induced by misfolded proteins. Nat Chem Biol 2010;6:900-906.

54. Song S, Kim SY, Hong YM, Jo DG, Lee JY, Shim SM, et al. Essential role of E2-25K/Hip-2 in mediating amyloid-beta neurotoxicity. Mol Cell 2003;12:553-563.

55. Tanno Y, Mori T, Yokoya S, Kanazawa K, Honma Y, Nikaido T, et al. Localization of huntingtin-interacting protein-2 (Hip-2) mRNA in the developing mouse brain. J Chem Neuroanat 1999;17:99-107.

56. de Pril R, Fischer DF, Roos RA, van Leeuwen FW. Ubiquitin-conjugating enzyme E2-25K increases aggregate formation and cell death in polyglutamine diseases. Mol Cell Neurosci 2007;34:10-19.

57. Song S, Lee H, Kam TI, Tai ML, Lee JY, Noh JY, et al. E2-25K/Hip-2 regulates caspase-12 in ER stress-mediated Abeta neurotoxicity. J Cell Bio 2008;182:675-684.

58. Duman RS, Li N, Liu RJ, Duric V, Aghajanian G. Signaling pathways underlying the rapid antidepressant actions of ketamine. Neuropharmacology 2012;62:35-41.

59. Browne CA, Lucki I. Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants. Front Pharmacol 2013;4:161.

60. Yu JJ, Zhang Y, Wang Y, Wen ZY, Liu XH, Qin J, et al. Inhibition of calcineurin in the prefrontal cortex induced depressive-like behavior through mTOR signaling pathway. Psychopharmacology (Berl) 2013;225:361-372.

61. Sun Q, Chen X, Ma I, Peng H, Wang F, Zha X, et al. Mammalian target of rapamycin-up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc Natl Acad Sci U S A 2011;108:4129-4134.

62. Abe Y, Sakairi T, Beeson C, Kopp JR. TGF-β1 stimulates mitochondrial oxidative phosphorylation and generation of reactive oxygen species in cultured mouse podocytes, mediated in part by the mTOR pathway. Am J Physiol Renal Physiol 2013;305:F1477-F1490.